Literature DB >> 29567478

Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.

Yuta Yamamoto1, Kenta Takei2, Sundaram Arulmozhiraja3, Vladimir Sladek4, Naoya Matsuo1, Song-Iee Han2, Takashi Matsuzaka5, Motohiro Sekiya5, Takaki Tokiwa6, Mitsuo Shoji7, Yasuteru Shigeta7, Yoshimi Nakagawa8, Hiroaki Tokiwa9, Hitoshi Shimano10.   

Abstract

Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor involved in the regulation of lipid homeostasis and improves hypertriglyceridemia. Pemafibrate is a novel selective PPARα modulator (SPPARMα) that activates PPARα transcriptional activity. Here, we computationally constructed the structure of the human PPARα in a complex with pemafibrate, along with that of hPPARα complexed with the classical fenofibrate, and studied their interactions quantitatively by using the first-principles calculations-based fragment molecular orbital (FMO) method. Comprehensive structural and protein-ligand binding elucidation along with the in vitro luciferase analysis let us to identify pemafibrate as a novel SPPARMα. Unlike known fibrate ligands, which bind only with the arm I of the Y-shaped ligand binding pocket, the Y-shaped pemafibrate binds to the entire cavity region. This lock and key nature causes enhanced induced fit in pemafibrate-ligated PPARα. Importantly, this selective modulator allosterically changes PPARα conformation to form a brand-new interface, which in turn binds to PPARα co-activator, PGC-1α, resulting in the full activation of PPARα. The structural basis for the potent effects of pemafibrate on PPARα transcriptional activity predicted by the in silico FMO methods was confirmed by in vitro luciferase assay for mutants. The unique binding mode of pemafibrate reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering cues for improving the binding affinity and selectivity of ligand for better clinical consequences. The findings explain the high affinity and efficacy of pemafibrate, which is expected to be in the clinical use soon.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fenofibrate; Fragment molecular orbital theory; Luciferase assay; Pemafibrate; Peroxisome proliferator-activated receptors; Protein-ligand interaction

Mesh:

Substances:

Year:  2018        PMID: 29567478     DOI: 10.1016/j.bbrc.2018.03.135

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Authors:  Jean-Charles Fruchart; Raul D Santos; Carlos Aguilar-Salinas; Masanori Aikawa; Khalid Al Rasadi; Pierre Amarenco; Philip J Barter; Richard Ceska; Alberto Corsini; Jean-Pierre Després; Patrick Duriez; Robert H Eckel; Marat V Ezhov; Michel Farnier; Henry N Ginsberg; Michel P Hermans; Shun Ishibashi; Fredrik Karpe; Tatsuhiko Kodama; Wolfgang Koenig; Michel Krempf; Soo Lim; Alberto J Lorenzatti; Ruth McPherson; Jesus Millan Nuñez-Cortes; Børge G Nordestgaard; Hisao Ogawa; Chris J Packard; Jorge Plutzky; Carlos I Ponte-Negretti; Aruna Pradhan; Kausik K Ray; Željko Reiner; Paul M Ridker; Massimiliano Ruscica; Shaukat Sadikot; Hitoshi Shimano; Piyamitr Sritara; Jane K Stock; Ta-Chen Su; Andrey V Susekov; André Tartar; Marja-Riitta Taskinen; Alexander Tenenbaum; Lale S Tokgözoğlu; Brian Tomlinson; Anne Tybjærg-Hansen; Paul Valensi; Michal Vrablík; Walter Wahli; Gerald F Watts; Shizuya Yamashita; Koutaro Yokote; Alberto Zambon; Peter Libby
Journal:  Cardiovasc Diabetol       Date:  2019-06-04       Impact factor: 9.951

2.  Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.

Authors:  Shizuya Yamashita; Hidenori Arai; Koutaro Yokote; Eiichi Araki; Mitsunori Matsushita; Toshiaki Nojima; Hideki Suganami; Shun Ishibashi
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

3.  Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model.

Authors:  Yohei Tomita; Nobuhiro Ozawa; Yukihiro Miwa; Ayako Ishida; Masayuki Ohta; Kazuo Tsubota; Toshihide Kurihara
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

Review 4.  Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.

Authors:  Yusuke Sasaki; Sana Raza-Iqbal; Toshiya Tanaka; Kentaro Murakami; Motonobu Anai; Tsuyoshi Osawa; Yoshihiro Matsumura; Juro Sakai; Tatsuhiko Kodama
Journal:  Int J Mol Sci       Date:  2019-11-13       Impact factor: 5.923

5.  Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations.

Authors:  Mayu Kawasaki; Akira Kambe; Yuta Yamamoto; Sundaram Arulmozhiraja; Sohei Ito; Yoshimi Nakagawa; Hiroaki Tokiwa; Shogo Nakano; Hitoshi Shimano
Journal:  Int J Mol Sci       Date:  2020-01-06       Impact factor: 5.923

Review 6.  Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases.

Authors:  Xiaozheng Dou; Adam S Duerfeldt
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

7.  Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism.

Authors:  Daiki Aomura; Makoto Harada; Yosuke Yamada; Takero Nakajima; Koji Hashimoto; Naoki Tanaka; Yuji Kamijo
Journal:  Metabolites       Date:  2021-06-09

Review 8.  Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Authors:  Jean-Charles Fruchart; Michel P Hermans; Jamila Fruchart-Najib
Journal:  Curr Atheroscler Rep       Date:  2020-07-15       Impact factor: 5.113

9.  The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.

Authors:  Masaya Araki; Yoshimi Nakagawa; Asayo Oishi; Song-Iee Han; Yunong Wang; Kae Kumagai; Hiroshi Ohno; Yuhei Mizunoe; Hitoshi Iwasaki; Motohiro Sekiya; Takashi Matsuzaka; Hitoshi Shimano
Journal:  Int J Mol Sci       Date:  2018-07-23       Impact factor: 5.923

10.  Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK.

Authors:  Ana Sandoval-Rodriguez; Hugo Christian Monroy-Ramirez; Alejandra Meza-Rios; Jesus Garcia-Bañuelos; Jose Vera-Cruz; Jorge Gutiérrez-Cuevas; Jorge Silva-Gomez; Bart Staels; Jose Dominguez-Rosales; Marina Galicia-Moreno; Monica Vazquez-Del Mercado; Jose Navarro-Partida; Arturo Santos-Garcia; Juan Armendariz-Borunda
Journal:  Hepatol Commun       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.